SeqOne advanced its position in clinical genomics this week, detailing the Spring 2026 release of its IVDR-certified platform with 72 new features and enhancements. The update prominently extends its DiagAI variant prioritization engine to structural variants and copy number variants, alongside new native whole-genome callers and a fully documented public API aimed at deeper integration.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The company introduced UP²-SV, a pathogenicity model trained on more than 65,000 ClinVar structural variants, reporting 97.6% pathogenic recall on a clinical diagnostic cohort. DiagAI also demonstrated strong performance on causal single nucleotide variants, with SeqOne rebuilding its interpretation environment to support cytoband navigation, BAF plots, and unified views across SNVs and SVs to improve clinical usability.
Operationally, SeqOne highlighted that its CE-IVD-certified platform is now deployed in more than 200 laboratories across over 30 countries, processing hundreds of thousands of genomic analyses annually. Case studies with European hospitals, including the University Hospital of Split and Hospital General Universitario de Alicante, showcased automated comprehensive genomic profiling workflows and exome sequencing pipelines validated for routine clinical use.
Additional collaborations with Hospital de Santa Maria in Lisbon, alongside PacBio and Agilent Technologies, underscored SeqOne’s role as the software layer converting sequencing data into structured clinical reports across germline, oncology, and infectious disease applications. These deployments illustrate growing integration of the platform into hospital environments and underline its relevance in rare disease and precision oncology diagnostics.
On the talent front, SeqOne is recruiting a remote Product Specialist in oncology and hematology, targeting candidates in Europe or Latin America with advanced bioinformatics or clinical genomics expertise. The role is focused on translating major oncology guidelines into product features, reinforcing the company’s emphasis on clinical-grade functionality and regulatory alignment as it scales internationally.
Taken together, the new DiagAI capabilities, expanded structural variant support, and deepening hospital collaborations enhance SeqOne’s competitive positioning in rare disease genomics and precision medicine software. While no financials or commercial adoption metrics were disclosed, the week’s developments point to a strengthening technology stack and growing clinical footprint that could support longer-term customer retention and recurring revenue growth.